title: [Drug eruptions in children in Cotonou, Benin].
abstract: BACKGROUND
  The aim of this study was to investigate the epidemiological aspects of drug eruptions in children in hospital area in Cotonou.
  
  
  METHODS
  A retrospective study was carried out in the Department of Dermatology of Cotonou (Benin) from 1998 to 2009. All cases of drug eruption occurred, during the study period, in children under 16 years old were selected for the study. The diagnosis of the drug eruption was based on clinical findings. The Identification of culprit drugs was based on the criteria as defined by the French Group of Pharmaco-vigilance.
  
  
  RESULTS
  From 1998 to 2009, 232 cases of drug eruption were diagnosed in the Department of Dermatology. Of this, 35 cases occurred in children under 16 years old. The patient mean age was 6.6 years with a sex ratio of 0.94. 4 patients were HIV positive. The culprit drug was identified in 21 patients (60%): sulfonamides 52.38% (11/21 cases), penicillin 9.52% (2 cases), vaccine 9.52% (2 cases), acetaminophen 9.52% (2 cases), acetyl salicylic acid 4.76% (n = 1), quinine 4.76% (n = 1), phenobarbital 4.76% (n = 1) and ceftriaxone 4.76% (n = 1). The main clinical patterns were: fixed drug eruption 45.71% (16/35), maculopapular rash 17.14% (n = 6), Stevens-Johnson syndrome 17.14% (n=6), and urticaria 8.57% (n = 3), 1 case of toxic epidermal necrolysis was seen and one patient died.
  
  
  CONCLUSIONS
  Skin reactions caused by drug intake are a rare disorder among children and fixed drug eruption is the main clinical presentation of the disease in Cotonou (Benin).
authors.affiliation: Service de Dermatologie-Venerologie. Centre National Hospitalier et Universitaire HKM Faculte des Sciences de la Sante de Cotonou BP 386 Cotonou Benin. adegbidih@yahoo.fr
authors.forename: H
authors.initials: H
authors.lastname: Adegbidi
authors.forename: F
authors.initials: F
authors.lastname: Atadokpede
authors.forename: G
authors.initials: G
authors.lastname: Sagbo
authors.forename: C
authors.initials: C
authors.lastname: Koudoukpo
authors.forename: M
authors.initials: M
authors.lastname: D'Almeida
authors.forename: J
authors.initials: J
authors.lastname: Teclessou
authors.forename: P
authors.initials: P
authors.lastname: N'Dah
authors.forename: A T
authors.initials: AT
authors.lastname: Djoonyam A Eroume
authors.forename: H G
authors.initials: HG
authors.lastname: Yedomon
authors.forename: F
authors.initials: F
authors.lastname: Do Ango-Padonou
mesh_terms: D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D001541:Benin / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D003875:Drug Eruptions / Q000453:epidemiology* / Q000209:etiology; D004890:Erythema / Q000139:chemically induced / Q000453:epidemiology; D005076:Exanthema / Q000139:chemically induced / Q000453:epidemiology; D005260:Female; D006785:Hospitals, University / Q000706:statistics & numerical data; D006801:Humans; D007223:Infant; D008297:Male; D012189:Retrospective Studies; D013262:Stevens-Johnson Syndrome / Q000453:epidemiology; D014581:Urticaria / Q000139:chemically induced / Q000453:epidemiology; D014612:Vaccines / Q000009:adverse effects
chemical_list: D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D014612:Vaccines